Eight years ago, a Dutch oncologist, John Haanen, set out to change melanoma treatment by arranging one of the largest and most rigorous trials ever for a cell therapy technique originally devised in the mid-’80s. He could not have picked worse timing.
Months after the trial began, European regulators approved the first PD-1 inhibitor, a groundbreaking immunotherapy. Patients clamored for it. “We had to wait,” Haanen said.
As the years passed, though, his study accrued patients who had exhausted PD-1s and provided a crucial lens on whether the decades-old approach, known as TIL therapy, could help patients who were out of options.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect